Liquidia (NASDAQ:LQDA) Now Covered by Oppenheimer

Oppenheimer started coverage on shares of Liquidia (NASDAQ:LQDA) in a report issued on Tuesday, Briefing.com reports. The brokerage set a “market perform” rating on the stock.

A number of other equities analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Liquidia in a report on Wednesday, May 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of Liquidia in a report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Liquidia Price Performance

NASDAQ LQDA opened at $12.60 on Tuesday. The business’s fifty day moving average price is $12.95 and its 200-day moving average price is $13.14. The stock has a market capitalization of $962.39 million, a price-to-earnings ratio of -8.08 and a beta of 0.25. Liquidia has a 1-year low of $5.71 and a 1-year high of $16.99.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.22). The firm had revenue of $2.97 million for the quarter, compared to the consensus estimate of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. Equities research analysts anticipate that Liquidia will post -1.2 EPS for the current year.

Insider Activity

In other news, CEO Roger Jeffs sold 8,360 shares of the business’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $121,888.80. Following the transaction, the chief executive officer now directly owns 826,985 shares in the company, valued at $12,057,441.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Roger Jeffs sold 8,360 shares of Liquidia stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $121,888.80. Following the sale, the chief executive officer now directly owns 826,985 shares of the company’s stock, valued at $12,057,441.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Russell Schundler sold 2,060 shares of Liquidia stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the sale, the general counsel now directly owns 486,027 shares in the company, valued at $7,086,273.66. The disclosure for this sale can be found here. Insiders have sold 18,653 shares of company stock worth $270,409 over the last ninety days. Corporate insiders own 31.60% of the company’s stock.

Institutional Trading of Liquidia

A number of large investors have recently modified their holdings of the company. Trexquant Investment LP purchased a new stake in Liquidia during the fourth quarter worth $770,000. LB Partners LLC purchased a new stake in Liquidia during the fourth quarter worth $3,404,000. Vestal Point Capital LP purchased a new stake in Liquidia during the fourth quarter worth $12,331,000. Kynam Capital Management LP increased its position in shares of Liquidia by 34.9% during the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Liquidia by 1.0% during the third quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock worth $17,590,000 after purchasing an additional 26,678 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).